The Global BRAF Kinase Inhibitors Market is Anticipated to Witness High Growth Owing to Increasing Cancer Incidences

Other

BRAF kinase inhibitors are molecular targeted therapies used for treatment of cancers like melanoma, lung cancer and colorectal cancer caused due to abnormality in BRAF gene. BRAF kinase inhibitors work by blocking the interaction of BRAF proteins with MEK proteins, thereby inhibiting downstream signaling of the MAPK pathway which drives uncontrolled cell growth. The increasing demand for targeted therapies and rising cancer burden globally is fueling the growth of BRAF kinase inhibitors market.

The global BRAF kinase inhibitors market is estimated to be valued at US$ 1364.56 billion in 2024 and is expected to exhibit a CAGR of 13% over the forecast period 2024 to 2031.

Key Takeaways

Key players: Key players operating in the BRAF kinase inhibitors market are Hoffmann-La Roche Ltd, Siemens Healthineers AG, Abbott Laboratories, Thermo Fisher Scientific Inc., Danaher Corporation, Sysmex Corporation, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Quidel Corporation, Hologic, Inc., Ortho Clinical Diagnostics, Beckman Coulter, Inc. (a subsidiary of Danaher Corporation), BioMÃ©rieux SA, Trinity Biotech plc, EKF Diagnostics Holdings plc.

Key opportunities: The rising prevalence of cancer globally especially lung cancer, colorectal cancer and melanoma presents lucrative opportunities for players in BRAF Kinase Inhibitors Market Demand Also, ongoing research on combination therapies and second generation BRAF inhibitors will further drive the market growth.

Global expansion: Major players are expanding their geographical reach through partnerships, acquisitions and new product launches to meet the increasing demand from international markets like Asia Pacific and Latin America.

Market drivers: Rapid increase in cancer incidence rates worldwide mainly due to changing lifestyle habits is a major market driver. According to WHO, cancer burden is expected to rise by 70% over the next 20 years. Growing awareness about targeted cancer therapies and their advantages over chemotherapy is augmenting the market growth.

Market restraints: High cost of targeted cancer therapies is a key challenge for market players. Also, complexity of dosing routines and safety issues associated with targeted therapies act as restraints for the BRAF kinase inhibitors market.

Segment Analysis

The BRAF Kinase Inhibitors market is dominated by the Kinevra segment which holds around 30% market share. Kinevra is used major cancer types like melanoma, thyroid cancer, colorectal cancer etc. as it selectively targets and blocks abnormal BRAF kinase activity which helps in slowing down the growth and spread of cancer cells. It is the most preferred treatment option among oncologists as it has shown promising results in clinical trials with minimal side effects.

The second largest segment is Tafinlar which has a market share of 20%. Tafinlar is also a BRAF inhibitor used for treating types of skin cancer called melanoma. It is primarily used for melanoma whose tumors have a change (mutation) in the BRAF gene that activates the BRAF protein and leads to cancer cell growth. Tafinlar works by blocking the BRAF protein in order to slow or stop the growth and spread of cancer cells.

Global Analysis

The North America region dominates the global BRAF Kinase Inhibitors market with over 40% share majorly driven by the US market. High adoption of targeted drugs for cancer treatment along with significant per capita healthcare expenditure and presence ofadvanced healthcare facilities have been driving the market growth. The Asia Pacific region is projected to grow at the fastest pace during the forecast period owing to increasing healthcare expenditure, growing incidence of cancers and rising medical tourism in the region.

Get More Insights On, BRAF Kinase Inhibitors Market

Explore More Related Topic On, Sustainable Packaging Market

About Author:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)

#BRAF Kinase Inhibitors Market Demand

Submitted 1 year 3 days ago by Sachin CMI.